The amount of acquisition cost of a business combination allocated to accounts payable and accrued expenses of the acquired entity. No authoritative reference available. No authoritative reference available. No authoritative reference available. The disclosure of the carrying value and fair value at the balance sheet date of forward exchange and option contracts classified as liabilities. No authoritative reference available. Amount of long-lived physical assets used in the normal conduct of business and not intended for resale. This can include land, physical structures, machinery, vehicles, furniture, computer equipment, construction in progress, and similar items. Amount does not include depreciation. An entity also may provide subtotals of geographic information about groups of countries; accordingly, this element also may be used to provide the amount of such long-lived assets for a group of countries. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a 2008 sale by the parent of a portion of its shares in a company. The sale of the shares represented by this element does not result in a loss of control by the parent. No authoritative reference available. Discount rate on probability-weighted cash flows No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Short-term securitiesreleased from a segregated custodial account pursuant to a custody agreement. No authoritative reference available. The market price per share of common stock. No authoritative reference available. This item represents the fair value of debt securities which are expected to mature after ten years and through fifteen years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. The number of shares held by Novartis AG at close of period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Premium percentage paid above market price for Alcon shares under the Purchase and Option Agreement. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of gain recognized in selling, general and administration expense related to the insurance settlement. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Threshold percentage not exceeded by the Company's largest minority interest holder after the 2008 stock transaction. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents carrying amount as of the balance sheet date for real estate held for productive use and alterations to land that improves its potential for use. Generally consisting of items having limited lives, such as walkways, driveways, fences, and parking lots, such improvements are depreciated over the useful lives of the subject assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of customers having over 10% of the consolidated sales for the period No authoritative reference available. No authoritative reference available. No authoritative reference available. Rental expense incurred for leased facilities owned by a related party's subsidiaries. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. All required disclosures by grouped ranges of option and share-settled stock appreciation right exercise prices, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents acquisition related activities which have taken place during the period in relation to assets measured at fair value on a recurring basis using unobservable inputs (Level 3). No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum number of Patents challenged by generic drug companies in ANDA filings No authoritative reference available. No authoritative reference available. No authoritative reference available. The exercise prices for purposes of disclosing shares potentially issuable share-settled stock appreciation rights and other required information pertaining to awards. No authoritative reference available. Amount of increase in the cost of share-based payments due to the acceleration of vesting No authoritative reference available. This item represents the disclosure related to Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities and the amortized cost and estimated fair value by maturity range. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents the fair value of debt securities which are expected to mature after fifteen years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. The amount of acquisition cost of a business combination allocated to in process research and development costs of the acquired entity. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares owned by majority shareholder. No authoritative reference available. No authoritative reference available. No authoritative reference available. The conditional date on which the special tax status will terminate. No authoritative reference available. Total amount of gain recognized in settlement of litigation. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a senior secured bank loans fund measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. Estimated rate pension costs were charged to retained earnings by the company after the adoption of accounting provision to measure the funded status of a plan utilizing alternate transition method. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of the cost of share-based payments that would have been recognized if the change of control had not occurred No authoritative reference available. The components of deferred income tax assets and (liabilities). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares held by Nestle at close of period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Information on sales and long lived assets for the entity's country of domicile and all individual countries where there is greater than 10% of total sales. Also sales information by ophthalmic market segment. No authoritative reference available. This element may be used to capture the complete disclosure pertaining to an accumulated other comprehensive income (loss). No authoritative reference available. Number of later issued patents included in the second infringement action. No authoritative reference available. No authoritative reference available. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the third year following the balance sheet date. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the sixth through the seventeenth year following the balance sheet date. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the fourth year following the balance sheet date. No authoritative reference available. Approximate reduction on number of employees as a result of disposal related to initiated programs to align operations with the evolving economic conditions and market environment. No authoritative reference available. The total number of patents related to Alcon's Patanol registered with the Canadian Patent Register No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The percentage of forfeitures to awards granted based on historical experience. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount the company reimbursed Nestle for fees paid to the Joint Administrators of Lehman Brothers International (Europe) London (in administration) related to the release of the short-term securities held in the custodial account. No authoritative reference available. Maximum number of patents challenged against Alcon products Patanol and Pataday anti-allergy ophthalmic solutions No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents the fair value of debt securities which are expected to mature after one year and through ten years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The minimum probability utilized on payment streams to determine cash flows to calculate the fair value of contingent payments on business acquisition. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Target allocation percentage in cash and cash equivalents to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. No authoritative reference available. The sum of the differences between the effective income tax rate and domestic federal statutory income tax rate attributable to all income tax settlements, amended returns and adjustments to estimates, during the period. No authoritative reference available. Number of generic drug companies included in patent infringement cases. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of employee positions eliminated in staffing reduction to align operations with the evolving economic conditions and market environment. No authoritative reference available. The amount of payments made by the Company for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net amount of charge-offs associated with trade receivables that have been determined to be uncollectible and/or amounts subsequently recovered. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average interest rate at the end of the reporting period on bank overdraft lines of credit. No authoritative reference available. This item represents investments in common and preferred stocks and other forms of securities that provide ownership interests in large cap foreign corporations that are included in the assets held in the defined benefit plan(s). This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. An agreement (contract) that requires the guarantor to make payments to the guaranteed third party reinsurer for the company's captive insurance subsidiaries. No authoritative reference available. The sum of the differences between the effective income tax rate and domestic federal statutory income tax rate attributable to losses on investments in a former subsidiary. No authoritative reference available. The approximate maximum number of performance share units originally approved (usually by shareholders and board of directors). No authoritative reference available. No authoritative reference available. No authoritative reference available. This text block may contain information related to interest income and interest expense for investments and borrowings with majority related party shareholder and its subsidiaries. No authoritative reference available. No authoritative reference available. No authoritative reference available. Represents the portion of interest incurred in the period on debt arrangements with Nestle and its subsidiaries that was charged against earnings. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average price as of the beginning of the year at which grantees can acquire the shares reserved for issuance under share-based plans excluding option plans. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of deferred tax assets for the differences between the values assigned and the tax bases of assets in a business combination. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of equity instruments other than options outstanding and currently exercisable under the stock option plan. No authoritative reference available. The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under share-settled stock appreciation rights and other required information pertaining to awards in the customized range. No authoritative reference available. The amount of change in the estimated accrued royalties payable. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares under a share-based award plan other than a stock option plan that were exercised during the reporting period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Pertains to term in years for the agreement with a related party for co-promotion of Lucentis. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the sixth through the tenth year following the balance sheet date. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The disclosure of the carrying value and fair value at the balance sheet date of liabilities for acquisition-related contingent payments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate that can be explained by other taxes paid under enacted tax laws during the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element captures stock options that were excluded from the diluted EPS calculation as they were anti-diliutive. No authoritative reference available. This amount represents total cost of purchased shares prior to termination of share repurchase program. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Dilutive effect using the treasury stock method for aggregate awards of share-settled restricted share units and performance share units to be issued to an employee under a share-based compensation arrangement. No authoritative reference available. The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance under the share-based plans excluding stock option plan. No authoritative reference available. This amount represents the total purchased shares prior to termination of share repurchase program. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum number of generic drug companies filing an ANDA seeking approval to sell a gneric version of a product No authoritative reference available. No authoritative reference available. No authoritative reference available. An assumption as to the rate of return on plan assets reflecting the average rate of earnings expected on the funds invested or to be invested to provide for the benefits included in the benefit obligation. No authoritative reference available. No authoritative reference available. No authoritative reference available. This table includes the change in net unrealized gains (losses) on investments, net of taxes, included in accumulated other comprehensive income (loss). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the operating cycle, if longer) under the Alcon Excess 401(k) Plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element may be used to disclose in its entirety the names of countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount as of the balance sheet date of the aggregate accrued product rebates that is expected to be paid within one year or the normal operating cycle, if longer. No authoritative reference available. Amount of cash paid to a shareholder for intangible asset to acquire the entity. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Dilutive effect using the treasury stock method for aggregate awards of share-settled stock appreciation rights to be issued to an employee under a share-based compensation arrangement. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element may be used to disclose in its entirety the names of countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. No authoritative reference available. Maximum probability assigned to contingent payment streams for objectives and milestones as a result of a business acquistion. No authoritative reference available. Value of Shares Issued, Net of Forfeitures During Period, Pursuant to any Share-Based Compensation Plan, Including Grant or Forfeitures of Restricted Shares, Vesting of Restricted Share Units, and Exercise of Options and/or Share-Settled Stock Appreciation Rights. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum percentage management believes it is reasonable possible that unrecognized tax benefits could increase in the next 12 months. No authoritative reference available. No authoritative reference available. No authoritative reference available. Pertains to cases filed in the Southern District of New York and Northern District of Texas that were consolidated to one class action case. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of trading securities included in hedge funds. No authoritative reference available. The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a restructuring. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of patents included in litigation alleging infringement of nanoparticle technology No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares purchased from Nestle prior to termination of share repurchase program. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element is made up of other investment funds not otherwise specified in the taxonomy, included in the assets of the defined benefit plan(s). This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. This element represents investments in cash and cash equivalents. This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available. Carrying amount, as of the balance sheet date, of other current assets which are not defined elsewhere in the taxonomy and which will be charged against earnings within one year or the normal operating cycle, if longer. No authoritative reference available. Number of case filed in the Eastern District of New York. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount paid by Company under the confidential Settlement and License Agreement for worldwide rights to sell Synergetics patented vitreoretinal products. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. Designated to encapsulate the entire footnote disclosure that provides information on the supplemental cash flow activities on cash, noncash or part cash transactions, for the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. The disclosure of the carrying value and fair value at the balance sheet date of forward exchange contracts classified as assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Percentage of the issued and outstanding stock that the number of shares that may be delivered pursuant to an exercise or after a lapse of a restriction period may not exceed. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of reimbursement to Novartis for certain operating expenses during the period. No authoritative reference available. The weighted average period between the balance-sheet date and expiration for all vested portions of equity instruments other than options outstanding and currently exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years. No authoritative reference available. Weighted average exercise price as of the balance sheet date for share-settled stock appreciation rights exercisable and outstanding. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The maximum probability utilized on payment streams to determine cash flows to calculate the fair value of contingent payments on business acquisition. No authoritative reference available. The tax effect as of the balance sheet date of the amount of the estimated future deductions arising from other liabilities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Cash equivalents on deposit with parent entity, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. The number of purchased common shares cancelled in current year which became effective after the fulfillment of certain formal law requirements. No authoritative reference available. Percentage of majority shareholder's shares to be sold at the first stage closing price of $143.18 per share in the second stage closing. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The estimated amortization period for acquired identifiable intangible assets based on the projected useful life of the products developed by the use of the technology. Acquired identifiable intangible assets include rights for the use of proprietary technologies for the development of products. No authoritative reference available. Amount of unremitted earnings of certain subsidiaries that are or will be reinvested indefinitely. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Tax charge for the write-off of deferred tax assets as a result of provisions of U.S. healthcare reform laws enacted during the period No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares into which fully or partially vested share-based awards other than options outstanding as of the balance-sheet date can be currently converted under the plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Liability recorded for potential cash payments that could result from acquisition-related contingent arrangements. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. A secured pediatric extension to the patent coverage for the patent in the second infringement action, which means the generic challenge on patent infringement poses no threat to the product market. No authoritative reference available. Maximum borrowing capacity under the commercial paper credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. No authoritative reference available. The amount of the excess employer contributions during the period under the Alcon Excess 401(k) Plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum amount of loss for any individual AFS investment during the period. No authoritative reference available. The amount of pension expense charged of the retained earnings, net of taxes, on adoption of new accounting provision. No authoritative reference available. The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under share-settled stock appreciation rights and other required information pertaining to awards in the customized range. No authoritative reference available. No authoritative reference available. No authoritative reference available. The dollar amount of the change if the probability of the assumptions would increase or decrease by 10%. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on shares under share-based plans excluding option plans during the reporting period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element describes an entity's accounting policy for comprehensive income. This disclosure may include a detail of the types of income included in comprehensive income and the methodologies and significant assumptions used to determine the amounts. No authoritative reference available. Items excluded from computation of diluted EPS as they were anti-dilutive. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position liability caption which represents a class of liabilities, or which may include an individual liability, measured at fair value on a recurring basis. No authoritative reference available. Amount of depreciation and amortization expense for the reportable segment. Must be disclosed if the amount (a) is included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) is otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of North American patent infringement actions filed by Alcon, either alone or jointly with its commercial partners No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of cases pending in District Court, Tarrant County, Texas. No authoritative reference available. The dollar amount received by the majority shareholder for each share of common stock sold in the 2008 stock transaction. No authoritative reference available. No authoritative reference available. No authoritative reference available. The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate shall be the regular tax rate if there are alternative tax systems. No authoritative reference available. The amount of co-promotion fees recognized in the period from an agreement with Novartis Pharma AG (an affiliate of Novartis) for the co-promotion under their license of the Lucentis product in Japan. No authoritative reference available. Contractual obligation to increase property, plant and equipment either through construction or future purchase over periods that initially exceed one year or the normal operating cycle, if longer. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Dividends payable in common shares. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of recognized charges in special termination benefits and amortization of prior service cost upon the change of control in the ownership No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the number of shares purchased by Novatis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of the change in the period in the valuation allowance for deferred tax assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. Disclosure of amortizable intangibles assets, in total and by major class, including the gross carrying amount and accumulated amortization and indefinite-lived intangible assets acquired. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. No authoritative reference available. No authoritative reference available. No authoritative reference available. The minimum value and liquidity of the underlying collateral of the amount advanced No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position liability caption which represents a class of liabilities, or which may include an individual liability, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The portion of the current period reduction in income tax expense due to the tax benefits from advances to and investments in a former subsidiary. No authoritative reference available. The weighted average fair value at grant for nonvested share-based awards issued during the period on other than stock option plans (for example, phantom stock plan, stock appreciation rights plan, performance target plan). No authoritative reference available. The weighted average price as of the balance-sheet date at which grantees could acquire the underlying shares with respect to all outstanding share-settled stock appreciation rights which are in the customized range of exercise prices. No authoritative reference available. Amount of gain recognized in cost of goods sold related to the insurance settlement. No authoritative reference available. Summary of stock options and share settled stock appreciation rights including rollforward of stock options and stock-settled stock appreciation rights, weighted-average exercise prices and weighted-average remaining contractual terms. No authoritative reference available. The weighted-average period remaining as of the balance-sheet date until option expiration pertaining to the outstanding share-settled stock appreciation rights for all plans in the customized range of exercise prices, which may be expressed in a variety of ways (for example, years, months). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount funded to a trust to defend the rights of minority shareholders. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after fifteen years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the assets of the defined benefit plan's Rabbi trust that include currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. No authoritative reference available. The initial date on which the special tax status will terminate. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The disclosure of the carrying value and fair value at the balance sheet date of interest rate swaps classified as assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of shares of acquiring company to be received by minority shareholders in exchange for each publicly traded Alcon share under terms of merger proposal. No authoritative reference available. Outstanding balance on guarantees to make payments to the guaranteed party based on certain customer's failure to pay specified obligations, such as debt, to a lender. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum borrowing capacity under the unsecured bank overdraft lines of credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. No authoritative reference available. Maximum amount of fee paid to parent company who guaranteed a bank loan. No authoritative reference available. No authoritative reference available. No authoritative reference available. The intrinsic value of exercisable awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee, as calculated by applying the disclosed pricing methodology. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents the fair value of investments in equity and other securities which are categorized neither as held-to-maturity nor trading. No authoritative reference available. Fees incurred related to portion of the costs of certain services including information technology licenses, corporate legal services, certain treasury and cash management activities and certain internal audit activities, based on arm's length prices, provided by Nestle. No authoritative reference available. The aggregate net prior service cost or credit recognized in other comprehensive income, including amounts arising during the period and reclassification adjustments of other comprehensive income as a result of being recognized as components of net periodic benefit cost for the period, net of tax. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Schedule of activities related to available-for-sale investments including proceeds from sales and principal repayments and realized gains and losses on sales. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Description of the interest rate on the loan swapped into as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets. No authoritative reference available. No authoritative reference available. No authoritative reference available. Value of shares cancelled and retired No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the assets of the defined benefit plan's Rabbi trust, specifically short-term investments. No authoritative reference available. No authoritative reference available. No authoritative reference available. The period of stay from Canadian Minister of Health as a result of lawsuit filing. The Canadian Minister of Health is required to delay approval of the product under litigation, which can only be shortened if the litigation is earlier resolved or the court modifies the stay on such approval. No authoritative reference available. The exercise price for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards. No authoritative reference available. This item represents Investments in equity and other securities, at cost, net of adjustments, which are categorized neither as held-to-maturity nor trading. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of gains/losses (realized and unrealized) from trading securities in the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The block of text includes the aggregate amount of amortization expense for finite lived intangible assets for the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The total amount of other operating cost and expense items. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of gains or losses recognized in net periodic benefit cost No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Target allocation percentage in global equity securities to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. No authoritative reference available. This element represents a certain statement of financial position liability caption which represents all liabilities, measured at fair value on a recurring basis. No authoritative reference available. This element primarily represents guaranteed investment contracts in Japan administered through insurance companies with guaranteed returns of .75%. The life insurance companies pool pension plan assets together from all the participating companies and generally invest in a relatively conservative asset mix of corporate and government bonds, mostly Japanese, with a minor portion in both domestic and foreign equity, loans and other investments. No authoritative reference available. The discount rate applied to probability-weighted future cash flows to determine the fair value of contingent payments on acquisition. No authoritative reference available. Amount of taxes not provided on temporary differences for permanent investments in certain subsidiaries No authoritative reference available. Common shares outstanding that were deferred into deferred compensation plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. This represents the number of shares purchased from the public under the pre-existing share repurchase program to be presented to the shareholders for retirement. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element captures share-settled stock appreciation rights that were excluded from the diluted EPS calculation as they were anti-dilutive. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average price at which grantees could have acquired the underlying shares with respect to share-based plans excluding option plans that lapsed during the reporting period. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of the change in the period in the total amount of unrecognized tax benefits excluding interest and penalties included in the tax reserves. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Gross amount of interest and penalties accrued as part of the tax reserves No authoritative reference available. No authoritative reference available. No authoritative reference available. Percentage of beginning balance of Level 3 trading securities that was realized and unrealized losses during the period. No authoritative reference available. The pretax change in incurred expenses related to the change of majority ownership and other costs to support the board of directors in its evaluation of merger proposal. These expenses were included in general corporate expenses No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents investments in common and preferred stocks and other forms of securities that provide ownership interests in corporations. This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element may be used to capture the complete disclosure pertaining to other current assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average interest rate at the end of the reporting period for all lines of credit. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of tax reserves, net of deposits with statutory authorities included in the consolidated balance sheet in other current liabilities No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The foreign currency translation recognized in other comprehensive income that is a reclassification adjustment of other comprehensive income as a result of being recognized as a component of net periodic benefit cost for the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of cases filed in the County Court at Law, Dallas County, Texas. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The aggregate net gain or loss recognized in other comprehensive income, including amounts arising during the period and reclassification adjustments of other comprehensive income as a result of being recognized as components of net periodic benefit cost for the period, net of tax. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. A summary of the compensation amount charged against income and the related income tax benefit for share based equity awards. No authoritative reference available. No authoritative reference available. No authoritative reference available. Total dividends paid on common stock. No authoritative reference available. Sensitivity to estimated fair value based on specific change in assumptions. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents corporate debt securities measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. The sum of the differences between the effective income tax rate and domestic federal statutory income tax rate attributable to the effect of provisions of U.S. healthcare reform legislation. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The sum of the differences between the effective income tax rate and domestic federal statutory income tax rate attributable to the effect of the change of majority ownership. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents Alcon's active balanced fund included in the assets of the defined benefit plan(s), that may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. Detail of current and deferred tax expense (benefit) from continuing operations No authoritative reference available. Represents the expense recognized during the period arising from share-based compensation arrangements (for example, shares of stock, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees, net of tax. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of curtailment gain that was offset against prior unrecognized losses No authoritative reference available. No authoritative reference available. No authoritative reference available. Income derived from investments in debt securities with Nestle and its subsidiaries, that was recorded in earnings. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Target allocation percentage in guaranteed investment contracts to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The decrease in the number of shares that could be issued attributable to the lapse of rights to exercise previously issued awards other than options under the terms of the agreements under the plan during the reporting period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Schedule of the gains and losses (realized and unrealized) on Level 3 financial instruments that was included in earnings during the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Reimbursement paid for expenses incurred by Nestles on behalf of the company for the release of the short-term securities held in the custodial account. No authoritative reference available. The weighted average interest rate at the end of the reporting period for all short-term related party borrowings. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents a certain statement of financial position asset caption which represents all assets, measured at fair value on a recurring basis. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the parent's shares of ownership interest in a company. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element may be used to capture the complete disclosure pertaining to an entity's dividends per share. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The block of text may include a description of the facts and circumstances on finite lived intangible assets and the estimated future amortization by year. This disclosure does not include goodwill. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents sales, issuances, and settlements (net) which have taken place during the period in relation to assets measured at fair value on a recurring basis using unobservable inputs (Level 3). No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the fifth year following the balance sheet date. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of days of exclusivity in which U.S. Food and Drug Administration where only one (or sometimes a few) generic manufacturers can produce the generic version of a drug. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Aggregate carrying amount, as of the balance sheet date, of other other noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer.) No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. For awards granted subsequent to January 2009 that retire prior to this age will forfeit some or all of the restricted share and restricted share units if the three year service period has not expired. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc., including expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, services, costs of public relations and corporate promotions are typically considered to be marketing costs. No authoritative reference available. The amount of trading securities included in fixed income funds. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element is made up of other investments not otherwise specified in the taxonomy, included in the assets of the defined benefit plan(s). This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. The amount of deferred tax liabilities for the differences between the values assigned and the tax bases of liabilities in a business combination. No authoritative reference available. This element represents carrying amount as of the balance sheet date for machinery, other equipment and software used in operation of the business. No authoritative reference available. This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after ten years and through 15 years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. Percentage of common stock publicly traded. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents guaranteed investment contracts included in the assets of the defined benefit plans(s), that may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares to be sold by Nestles at the first stage closing price of $143.18 per share. No authoritative reference available. No authoritative reference available. No authoritative reference available. The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on equity instruments other than options which were exercised (or share units converted) into shares during the reporting period under the plan. No authoritative reference available. The number of years following a change of control when the change of control provisions impact vesting (in years) No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount of borrowing capacity, with related parties, currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding. No authoritative reference available. Amount of temporary differences related to permanent investment in certain subsidiaries. No authoritative reference available. Amount of tax reserves, net of deposits with statutory authorities included in the consolidated balance sheet in other long term liabilities No authoritative reference available. Threshold amount of recovery sought by litigating counterparty. No authoritative reference available. Summary of restricted shares and share-settled restricted share units including rollforward of restricted shares and share-settled restricted share units, weighted-average exercise prices and weighted-average remaining contractual terms. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. For awards granted prior to January 2006, early retirement at this age makes the award exercisable. No authoritative reference available. The number of shares reserved for issuance pertaining to the outstanding share-settled stock appreciation rights as of the balance sheet date for all plans in the customized range of exercise prices. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Percentage of subsidiary's or equity investee's stock owned by parent company after the 2008 stock transaction. No authoritative reference available. This element represents a sale by the parent of a portion of its shares in a company. The sale of the shares represented by this element does not result in a loss of control by the parent. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents investments in debt securities. This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. Amount of revenue from external customers attributed to an individual country from which revenue is material. An entity also may provide subtotals of geographic information about groups of countries. No authoritative reference available. The number of months preceding a change of control when the change of control provisions impact vesting (in months) No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum number of patents challenged against Alcon products Travatan and Travatan Z ophthalmic solutions No authoritative reference available. Number of patents included in first infringement action. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average price at which grantees could have acquired the underlying shares with respect to shares under share-based plans excluding option plans that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. No authoritative reference available. Represents the expense recognized during the period arising from share-based compensation arrangements (for example, shares of stock, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees, excluding the portion that was previously capitalized. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amounts recognized in other comprehensive income (but not yet recognized in net periodic benefit cost), including the net gain (loss) and net prior service cost (credit) arising during the period, net of tax. Also includes reclassification adjustments out of other comprehensive income as a result of being recognized as components of net periodic benefit cost for the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The maximum value and liquidity of the underlying collateral of the amount advanced No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of patents challenged by Sandoz ANDS on Alcon's Patanol No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. A summary of share-based compensation fair value assumptions and methodology for performance share units. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the second year following the balance sheet date. No authoritative reference available. No authoritative reference available. No authoritative reference available. The number of shares reserved for issuance pertaining to the outstanding exercisable share-settled stock appreciation rights as of the balance-sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. No authoritative reference available. The amount of net assets acquired of the acquired entity. No authoritative reference available. The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws, expiring in the twelve months following the balance sheet date. No authoritative reference available. Minimum percentage management believes it is reasonable possible that unrecognized tax benefits could decrease in the next 12 months. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The weighted average period between the balance-sheet date and expiration for all awards outstanding under the plan, which may be expressed in a decimal value for number of years. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element includes supplemental information for various accounts on the balance sheet. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the change in the fair value of the irrevocable Rabbi trust which is held and invested in an unfunded arrangement for the payment of benefits to participants under certain defined benefit pension plans of the company. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of the expenses related to the change of majority ownership that related to share-based compensation expense. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents purchases which have taken place during the period in relation to assets measured at fair value on a recurring basis using unobservable inputs (Level 3). No authoritative reference available. The reduction in income tax expense due to specific period items. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on equity instruments other than options which were exercised (or share units converted) into shares during the reporting period under the plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. This amount represents number of shares authorized to purchase under pre-existing share repurchase program. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the benefits (as of the date of the latest statement of financial position presented), expected to be paid in each of the next five years, and in the aggregate for the next succeeding five years. The expected benefits should be estimated based on the same assumptions used to measure the company's benefit obligation at the end of the year and should include estimated future employee service. No authoritative reference available. Fair value of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). No authoritative reference available. Minimum probability assigned to contingent payment streams for objectives and milestones as a result of a business acquistion. No authoritative reference available. The proceeds from the sale of Level 3 trading securities. No authoritative reference available. The period of U.S. Food and Drug Administration stay as a result of lawsuit filing. The U.S. Food and Drug Administration is required to delay approval of product, unless the litigation were earlier resolved or the court were to modify the stay on approval. No authoritative reference available. For awards granted subsequent to January 2006 through December 2008 that retire prior to this age will forfeit some or all of the restricted share and restricted share units if the three year service period has not expired. No authoritative reference available. A schedule of the required quarterly information. No authoritative reference available. No authoritative reference available. No authoritative reference available. Customers having greater than this percentage of consolidated sales are considered significant customers and are disclosed individually. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum ownership percentage required of the parent to prevent acceleration of obligation to pay outstanding principal by entity. No authoritative reference available. Shares purchased from the market prior to termination of share repurchase program. No authoritative reference available. This element is the total fair value of the assets in the US defined benefit plan. No authoritative reference available. Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of taxbefore reclassification adjustment. No authoritative reference available. Number of later issued patents owned by Alcon that cover the Pataday formulation Sandoz is challenging. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Outstanding balance of guarantees of payment of a specified financial obligation if defined events occur or fail to occur. No authoritative reference available. No authoritative reference available. No authoritative reference available. A summary of share-based compensation fair value assumptions and methodology for stock options and share-settled stock appreciation rights. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The dollar amount of sales recorded by the major customer. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Detail of income from country of domicile and from all other countries. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Percent increase or decrease in the probability assumptions. No authoritative reference available. This element is the total of net periodic benefit costs of the defined benefit plan(s) recognized during the period as well as the increase or decrease in plan assets and benefit obligations recognized in other comprehensive income. No authoritative reference available. No authoritative reference available. No authoritative reference available. Weighted average price per share in cash of stock purchased in the second stage closing pursuant to the Purchase and Option Agreement. No authoritative reference available. Amount of instruments that were tri-party fully collateralized reverse repurchase agreements included in cash equivalents No authoritative reference available. Describes an entity's accounting policy for its treasury shares. No authoritative reference available. The total liability outstanding related to cash-settled stock appreciation rights. No authoritative reference available. The amount of increase in the plan assets attributed to business combinations or the conversion of a multi-employer plan to a single-employer plan. No authoritative reference available. Amount of withholding taxes not provided on unremitted earnings of certain subsidiaries. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Write-off of deferred tax asset due to U.S. enactment of the Health Care and Education Reconciliation Act of 2010 No authoritative reference available. This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. No authoritative reference available. The amount of unrecognized tax benefits that would impact the effective tax rate if recognized. No authoritative reference available. Majority ownership percentage upon consummation of stock purchased after the second stage closing pursuant to the Purchase and Option Agreement. No authoritative reference available. This amount represents the maximum purchase amount authorized provided by the board of directors under share repurchase program. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after one year and through ten years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. Summary of performance share units including rollforward of performance share units, weighted-average exercise prices and weighted-average remaining contractual terms. No authoritative reference available. Schedule of the components of the purchase price of the various acquisitions. This schedule does not include leveraged buyouts. No authoritative reference available. No authoritative reference available. No authoritative reference available. Target allocation percentage of investments in corporate bonds to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of the Company's subsidiaries included in litigation alleging infringement of patents on nanoparticle technology No authoritative reference available. This item represents investments in common and preferred stocks and other forms of securities that provide ownership interests in large cap US corporations. This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount of payments made by the trust for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. No authoritative reference available. The adjustment for the difference in the original purchase price and the final amount that was paid to non-controlling interest shareholders. No authoritative reference available. This element includes information about debt securities (such as bonds), that may be included in the assets of the defined benefit plan(s), issued by a national, local, or municipal government, agency or corporation. This element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No authoritative reference available. No authoritative reference available. No authoritative reference available.